S

Sanofi

Global pharma company; vaccines and R&D

Human Factors and Usability Engineering Director

Full-TimeUpdated on 10/23/2026Deadline 11/18/26
$178.5k - $257.8k
Expert
Bachelor's, Master's
Cambridge, MA, USA+1 moreMore locations: Morristown, NJ, USA
In Person
Product & Experience DesignUX Research

About the job

Requirements
  • A bachelor's or master's degree in Human Factors Engineering, Psychology, Biomedical Engineering, Industrial Design, or a related field is required.
  • At least 10 years of progressive experience in Human Factors and Usability Engineering, including demonstrated experience in combination product development across therapeutic areas and regulatory pathways, is required.
  • A track record of delivering regulatory-compliant Human Factors and Usability Engineering solutions for combination products, from feasibility through Lifecycle Management, is required.
  • Experience leading complex, high-stakes Human Factors and Usability Engineering programs with minimal oversight is required.
  • Experience supporting or leading health authority interactions with the Food and Drug Administration, European Medicines Agency, Notified Bodies, and National Medical Products Administration is required.
  • Mastery of FDA Human Factors guidance, IEC 62366-1:2015+A1:2020, ISO 14971:2019, ISO 13485, HE75, and EMA guidelines is required.
  • Deep expertise in the Human Factors and Usability Engineering lifecycle is required, including user needs, use requirements, context of use, Known Use Problems, Use-Related Risk Analysis, generative, formative, and summative study design and execution, Usability Engineering File and Design History File documentation, and regulatory submission strategy.
  • Ability to establish user needs, translate them into user requirements, and drive user-centric user interface design decisions is required.
  • Experience contributing to Human Factors and Usability Engineering regulatory submissions and health authority interactions across multiple combination product types and regulatory pathways is required.
  • Ability to influence cross-functional teams and drive Human Factors and Usability Engineering integration across complex, matrixed organizations without formal authority is required.
  • Experience mentoring and developing Human Factors and Usability Engineering professionals and contributing to organizational capability is required.
  • Ability to contribute to and advance Human Factors and Usability Engineering processes, standards, and best practices at a team or organizational level is required.
Responsibilities
  • Lead complex, high-stakes Human Factors and Usability Engineering programs across the Global Device and Packaging Unit portfolio with minimal oversight, owning deliverables across the full product lifecycle from early-stage user needs through Lifecycle Management.
  • Drive the full Human Factors and Usability Engineering lifecycle hands-on, including user needs, use requirements, context of use, Known Use Problems, Use-Related Risk Analysis, generative, formative, and summative study design and execution, Usability Engineering File and Design History File documentation, and regulatory submission strategy.
  • Shape and advance the Human Factors and Usability Engineering vision, strategy, and roadmap in partnership with the Senior Director, aligning it with product development priorities and evolving global regulatory expectations.
  • Lead and support external health authority engagement and regulatory interactions across combination products, medical devices, and Software as a Medical Device.
  • Establish, harmonize, and continuously improve Human Factors and Usability Engineering processes, methodologies, tools, and templates to support scalability, consistency, and alignment with current FDA, EMA, and international standards.
  • Influence clinical, regulatory, device, and quality/risk teams to embed user-centered design principles throughout product development without formal authority.
  • Mentor and develop Human Factors and Usability Engineering professionals, contributing to organizational capability, scientific rigor, and continuous improvement.
  • Advance Human Factors and Usability Engineering as a strategic differentiator through thought leadership, contributions to industry standards, and organizational best-practice development.
Desired Qualifications
  • Expertise in combination product Human Factors and Usability Engineering across multiple therapeutic areas, including parenteral delivery systems such as autoinjectors, prefilled syringes, pens, or large-volume devices.
  • Professional experience beyond Human Factors and Usability Engineering in design disciplines such as user-centric, industrial, Instructions for Use, or graphic design; engineering fields such as device, systems, or quality engineering; regulatory and risk management; requirements generation; clinical practice; or post-market activities.
  • Experience with emerging technologies, including Software as a Medical Device, digital health, and artificial intelligence or machine learning in medical devices.
  • A track record of advancing Human Factors and Usability Engineering practices and methodologies within organizations.
  • Experience with portfolio-level Human Factors and Usability Engineering strategy and cross-functional governance.
  • Broad therapeutic-area experience spanning monoclonal antibodies, vaccines, peptides, genomics, and/or small molecules.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...